NPM1 and acute myeloid leukemia: In our multi-centric, real-life study including younger AML patients homogeneously treated with FLAI regimen, NPM1 mut patients had a very good long-term outcome and concomitant FLT3-ITD mutation did not impact on survival, regardless of allelic burden.